Lactate Metabolism in the Hypoperfused Critically Ill
Status
Conditions
Treatments
Details and patient eligibility
About
Investigating lactate metabolism in critically ill patients whom are hypoperfused by preforming metabolomics via liquid chromatography-mass spectrometry.
Full description
Lactate concentration is well known to be directly correlated with risk of death during admission to intensive care. However, lactate by itself is not considered toxic. The study is observational. The breakdown of lactate is being investigated by collecting blood- and urinsamples from patients with hyperlactatemia as a result of hypoperfusion. Levels of lactate, and known as well as unknown metabolites will be identified and quantified by metabolomics. Metabolomics is performed using a combination of liquid chromatography and mass spectrometry. Data will be analysed via statistical analysis to investigate corelations between lactate, a given metabolite and hard outcome such as mortality. And thereby lay the groundwork for potential further research regarding specific lactate-metabolites.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Diagnosed with sepsis/septic shock or severe heart failure.
- Clinical and paraclinical signs of hypoperfusion in relation to abovementioned diagnosis.
- Metabolic acidosis with s-lactate equal-to-or-above 4 mmol/l.
- Incapacitated
Exclusion criteria
- Only regional hypoperfusion such as a leg.
- Receiving intravenous lactate as part of treatment.
- Going in to dialysis. The exclusion is only during dialysis treatment.
Trial design
20 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Henrik Wolsted, MD; Jesper H Kilbak, Stud. scient.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal